RESEARCH ARTICLE

Open Access



DISCONTOOLS: a database to identify research gaps on vaccines, pharmaceuticals and diagnostics for the control of infectious diseases of animals

Declan O'Brien^{1*}, Jim Scudamore², Johannes Charlier³ and Morgane Delavergne¹

Abstract

Background: The public and private sector in the EU spend around €800 million per year on animal health and welfare related research. An objective process to identify critical gaps in knowledge and available control tools should aid the prioritisation of research in order to speed up the development of new or improved diagnostics, vaccines and pharmaceuticals and reduce the burden of animal diseases.

Method: Here, we describe the construction of a database based on expert consultation for 52 infectious diseases of animals.

Results: For each disease, an expert group produced a disease and product analysis document that formed the basis for gap analysis and prioritisation. The prioritisation model was based on a closed scoring system, employing identical weights for six evaluation criteria (disease knowledge; impact on animal health and welfare; impact on public health; impact on wider society; impact on trade; control tools). The diseases were classified into three groups: epizootic diseases, food-producing animal complexes or zoonotic diseases.

Discussion: The highly ranked diseases in the prioritisation model comprised mostly zoonotic and epizootic diseases with important gaps identified in vaccine development and pharmaceuticals, respectively. The most important outcome is the identification of key research needs by disease. The rankings and research needs by disease are provided on a public website (www.discontools.eu) which is currently being updated based on new expert consultations.

Conclusion: As such, it can become a reference point for funders of research including the European Commission, member states, foundations, trusts along with private industry to prioritise research. This will deliver benefits in terms of animal health and welfare but also public health, societal benefits and a safe and secure food supply.

Keywords: Prioritisation, Animal disease, Research needs, EU

Background

Animal diseases are estimated to reduce the production of animal products by at least 20% according to the World Organisation for Animal Health (OIE) [1]. As such, the prevention and control of animal diseases has benefits in terms of animal health and welfare but also human health where zoonoses are concerned and broad societal benefits in terms of companion animal health and the security of a safe food supply. In terms of funding, it is estimated that the public sector spends \notin 400 million per year in Europe on animal health and welfare related research [2, 3] and the private sector spends \notin 400 million per year on animal health research [4]. With about \notin 800 million being spent per year, the added value of an objective process to prioritise critical research can be appreciated. By focusing a proportion of this expenditure on critical gaps in priority diseases, it will be possible to speed up the development and delivery of new and improved disease control tools including diagnostics, vaccines and pharmaceuticals to reduce the burden of disease on animals. Given that the current value of animal based products at producer prices in the E.U. is \notin 154 billion per year [5], every percentage



© The Author(s). 2017 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*} Correspondence: declanjobrien@hotmail.com

¹International Federation for Animal Health Europe, Avenue de Tervueren 168, box 81150 Brussels, Belgium

Full list of author information is available at the end of the article

reduction in the impact of animal disease on production would be of major economic importance.

During the work of the European Technology Platform for Global Animal Health (ETPGAH)¹ from 2004 to 2012, it was recognised that disease prioritisation was one of the most important initiatives that needed to be undertaken to focus and prioritise research [6]. This work necessitates the identification of gaps in knowledge as well as control tools – diagnostics, vaccines and pharmaceuticals.

The DISCONTOOLS project was funded under the EU 7th framework programme from 2008 to 2013 and originated from the Action Plan of the ETPGAH. The general objective of the project was to evaluate global animal health priorities and the risk they could pose to the European Union. This understanding would assist in ensuring the most effective allocation of research funding. The project led to the development of a disease database containing a gap analysis and prioritisation model for 52 infectious diseases of animals. The objective of this paper is to describe the different steps in the development of the database (Section Construction and content), describe its utility (Section Utility) and discuss how it could assist policy makers in targeting research funding (Section Discussion). It should be noted that the focus of the database is on research needs with respect to control tools in the form of diagnostics, vaccines and pharmaceuticals. It does not necessarily consider disease control strategies or other aspects of disease control such as disease modelling, surveillance and regulatory support.

Methods

General approach

The DISCONTOOLS project was organised as shown in Fig. 1. All European and Global organisations with an interest in animal health research were invited to join

the Stakeholder Forum. It included organisations ranging from farmers, veterinarians and the pharmaceutical industry to chief veterinary officers, research institutes and related projects funded by the European Commission. The Project Management Board (PMB) comprised 10 representatives from the Stakeholders selected to represent research, industry, users and public bodies. The membership is listed in Table 1.

Five work packages or working groups were established each reporting to the PMB. Of these two working groups one on disease prioritisation, the other on gap analysis were involved in developing the database (See Fig. 1). Membership of the two working groups consisted of approximately 15 people and was by invitation along with nominations from the stakeholders and interested parties. It was important that each of the groups was balanced with members with appropriate expertise from research, industry, users (including farming and veterinary profession) and regulators as well as the European Commission and international organisations.

The development of the database was preceded by a review of existing processes for prioritisation and gap analysis by the PMB in order to steer the methodology adopted. Subsequently, the disease list was selected and prioritisation methodology developed, followed by expert opinion elicitation to provide content to the database. The prioritisation methodology was subdivided in the development of Disease & Product analysis document (D&P), a prioritisation model and gap analysis model.

Review of existing prioritisation models

A worldwide review of existing models was carried out. In public health, a number of studies have methodically prioritised communicable diseases and pathogens [7–15]. In the field of animal health, most studies have focused on



Table 1 Organisations represented in the Project Management

 Board of DISCONTOOLS

Organisation	Description
Copa-Cogeca	European union for agricultural organisations and cooperatives
CVO's	Chief Veterinary Officers
DG Research	Directorate-General for Research and Innovation of the European Commission
EAEVE	European Association of Establishments for Veterinary Education
EMIDA ERA-net	Coordination platform of research on emerging infectious diseases of animals
EMVD	European Manufacturers of Veterinary Diagnostics
EPIZONE	International network of veterinary research institutes working on epizootic animal diseases
FVE	Federation of Veterinarians of Europe
HMA	Heads of Medicines Agencies
IFAH-Europe	International Federation for Animal Health Europe
MEDVETNET	European Network of Excellence for Zoonoses Research
OIE	World organisation for animal health

prioritisation of food-borne and zoonotic pathogens [13, 16–20]. In addition, studies have also been conducted with the specific aims of prioritising surveillance of wildlife pathogens [21], disease control for poverty alleviation [22], non-regulatory animal health issues [23] and exotic diseases and emerging animal health threats [24, 25].

Although methodological approaches differ, prioritysetting studies typically follow a series of steps: (i) selecting a group of diseases/pathogens for prioritization; (ii) identifying a list of appropriate and measurable criteria to assess diseases/pathogens; (iii) defining a range of levels for each criterion; (iv) determining the relative importance by means of a weight or score for each level and criterion; (v) aggregating to produce an overall score for each disease/pathogen; and (vi) ranking diseases/pathogens by their overall score to derive a recommended list for prioritization [26]. It was evident that risk-based prioritysetting should be systematic, flexible, reproducible and informative to public policy. The criteria must be explicit, measurable, relevant and objective wherever possible. However, the methodology and criteria required will depend on the goal of prioritisation, so a clear definition of the aim is essential. The priority-setting process should be transparent and open to discussion and revision. In addition, it is considered preferable to define a disease as specifically as possible (e.g. brucellosis of cattle versus brucellosis in general) and to consider how the model can evolve over time in order to remain of value. On the basis of the review, and considering the goal of DISCONTOOLS, i.e. identifying research needs of infectious animal diseases in the EU, the main steps which have been followed include establishing a list of relevant infectious diseases and gathering relevant information on each disease. It was considered essential that the scoring system allows diseases to be ranked based on total scores and/or on scores for particular criteria (e.g. impact on public health).

Establishment of disease list

The working groups of the DISCONTOOLS project were created by inviting stakeholders to become involved in WP2, WP3 and/or WP4 with the PMB taking care of WP1 and WP5 (see Fig. 1). In parallel, the PMB invited an expert to Chair each of WP2, WP3 and WP4. The WPs then established a list of 52 priority diseases to be included in the prioritisation exercise. The starting point for the list of diseases was from the Action Plan of the ETPGAH which referred to 47 diseases. In addition, it was considered important not to lose sight of endemic diseases or disease syndromes (e.g. internal parasites, mastitis). Therefore, 3 groups of diseases were defined as follows:

- (1)epizootic diseases: infectious diseases which pose a risk for introduction or spread in the EU and for which tools for optimum detection, surveillance and control would be beneficial;
- (2) food producing animal complexes: major enzootic diseases of livestock in Europe;
- (3)zoonotic diseases: infectious diseases of animals that are important for human health and for their socio-economic effects.

The geographic dimension of the project was primarily European. Naturally, where a disease was not present in Europe, a global perspective was taken into account. The expert groups were asked to highlight and take into account strains and species where the economic impact was the highest not only in Europe, but worldwide.

After discussions of the working groups of DISCONTOOLS a final list of 52 diseases was agreed. The list was not considered to be exhaustive, but representative of most disease scenarios. Infectious diseases of aquatic animals or companion animals without a zoonotic implication were not considered.

Results

Prioritisation methodology

Disease and product analysis document

A D&P was developed for each disease by the working groups of the DISCONTOOLS project in order to have key information available prior to scoring of the different criteria. The D&P is a reference document that provides the detailed and relevant information for each disease which is necessary to support the scoring for the prioritisation and gap analysis models. It contains 23 main sections with sub-headings covering a wide range of aspects such as description and characteristics of the disease, route of transmission, zoonotic potential, control tools available, and socio-economic impact. The full list of sections may be consulted at www.discontools.eu/diseases under the custom report section. For each section, an additional column headed "Gaps identified" was included in the D&P to gather further information on the gaps in knowledge and products of each disease. The document was completed by the expert groups who were asked to reach a consensus on the final text which was then reviewed by the PMB.

Prioritisation model

The criteria, levels within each of the criteria, scores and weighting coefficients that were used in the prioritisation model can be viewed in Table 2. Six criteria were considered:

Table 2 The prioritisation model: criteria considered, levels within the criteria, scores and applied weighting coefficients (Coef)

Criteria			Scores Coef To				
Disease knowledge	0	1	2	3	4	2.5	/100
1. Speed of spread							
2. Number of species involved							
3. Persistence of infectious agent in the environment							
4. Risk of spread to susceptible populations							
5. Potential for silent spread							
6. Wildlife reservoir and potential spread							
7. Vector reservoir and potential spread							
8. Variability of the agent							
9. Understanding of fundamental immunology							
10. Host pathogen interaction							
Impact on animal health and welfare	0	1	2	3	4	8.33	/100
1. Disease impact on production							
2. Duration of animal welfare impact							
3. Proportion of animals affected and suffering pain/injury/distress as a result of the disease							
Impact on public health – human health	0	1	2	3	4	4.16	/100
1. Impact of occurrence on human health							
2. Likelihood of occurrence							
3. Impact of occurrence on food safety							
4. Transmissibility (spread from animals to humans)							
5. Spread in humans							
6. Bioterrorism potential							
Impact on wider society	0	1	2	3	4	8.33	/100
1. Economic direct impact (including cumulative cost, e.g. enzootic vs. epizootic)							
2. Economic indirect impact (social, market)							
3. Agriterrorism potential							
Impact on trade	0	1	2	3	4	6.25	/100
1. Impact on international trade due to existing regulations							
2. Impact on EC trade due to existing regulations							
3. Potential for regionalisation							
4. Impact on security of food supply							
Control tools	+2	+1	0	-1	-2	16.66	/100
1. Appropriate diagnostics							
2. Appropriate vaccines							
3. Appropriate pharmaceuticals							
Total Score							

(1)disease knowledge
(2)impact on animal health and welfare
(3)impact on public health
(4)impact on wider society
(5)impact on trade
(6)control tools

An interpretation guide (http://www.discontools.eu/upl/ 1/default/doc/1233_PrioInterV3-1-20110303.pdf) was developed to help the expert groups decide on the appropriate scores to apply to each criterion. The expert groups were asked to reach a consensus for the scoring of each criterion. A 5 - tiered scoring system was chosen as this appeared to offer a greater flexibility across the various criteria. The scoring scale applied to the 5-tiered system is as follows: for the first five sections 0, +1; +2; +3; +4 are used; for the sixth section dealing with control tool scores of +2; +1; 0; -1; -2 are used. This scoring scale was selected to highlight the differences in control tools for each disease in the sense that if for a particular disease a vaccine exists that has a high level of efficacy, quality, safety and availability, then a negative score will be attributed to the final total score of the concerned disease to diminish its priority as an effective tool is available. On the contrary, if control tools are missing, then a positive score will be added to the total score meaning that the disease will be higher in the prioritised list of diseases.

The weighting coefficient for each level of a criterion was computed as follows:

$$W = \frac{100}{X * I}$$

where W = the weighting coefficient, X is the maximum score of a level within a criterion and I is the number of levels within a criterion. This ensured that the maximum score of each criterion was 100 and that the different criteria were attributed the same weight in the overall score.

As there are 6 criteria for each disease, the scores could be grouped, listed, ranked or presented in a wide range of ways using either the overall score or the individual scores for each criteria.

Gap analysis model of control tools

The criteria, levels within each of the criteria, scores and weighting coefficients that were used in the gap analysis model can be viewed in Table 3. Gap analysis considered 3 areas: diagnostic, vaccine and pharmaceutical gaps. The scoring system goes from +2 (important gap) to -2 (current tools are appropriate and no need to focus research in this area). As with the prioritisation model, an interpretation guide was developed to facilitate consistency in scoring (http://www.discontools.eu/upl/1/default/doc/ 1235_GapAna-Inter-V3-1.pdf).

Table 3 The ga	ap analysis moo	del: criteria consi	dered, levels within
the criteria, scor	es and applied	weighting coeff	ficients (Coef)

Diagnostic tools 2 1 0 -1 -2 4.17 /100 1. Availability ^a 2 Prevention and control - Differentiation of infected from vaccinated (DIVA) 3. Strategic reserve 4. Capacity of production 5. Market potential -	Criteria	Sc	ore	25	,		Coef	Total (score*coef
 1. Availability^a 2. Prevention and control - Differentiation of infected from vaccinated (DVA) 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability durability 8. Sensitivity 9. Specificity 10. Reproducibility 11. Simplicity/ease of use 12. Speed Vaccination tools 2 7. Couality/stability durability³ 2. Monitoring for infection in a vaccinated population vaccinated population 5. Market potential 6. Affordable 7. Quality/stability 8. Safety of production 9. Sfrategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 12. Speed 13. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 14. Vailability³ 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety animal 9. Safety animal 9. Safety environment 11. Resistance Tutal Score: 	Diagnostic tools	2	1	0	-1	-2	4.17	/100
 2. Prevention and control - Differentiation of infected from vaccinated (DIVA) 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability durability 8. Sensitivity 9. Specificity 10. Reproducibility 11. Simplicity/ease of use 12. Speed Vaccination tools 2 I I I I I I I I I I I I I I I I I I I	1. Availability ^a							
3. Strategic reserve 4. Capacity of production 5. Market potential 5. Market potential 6. Affordable 7. Quality/stability durability 8. Sensitivity 9. Specificity 10. Reproducibility 11. Simplicity/ease of use 12. Speed 2 1 0 -1 -2 4.55 /100 1. Commercial availability ⁴ 2. Monitoring for infection in a vaccinated population 5. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability 8. Safety of vaccines 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 9 <td>2. Prevention and control - Differentiation of infected from vaccinated (DIVA)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	2. Prevention and control - Differentiation of infected from vaccinated (DIVA)							
4. Capacity of production 5. Market potential 5. Market potential 6. Affordable 7. Quality/stability durability 8. Sensitivity 9. Specificity 10. Reproducibility 10. Reproducibility 11. Simplicity/ease of use 12. Speed 2 1 0 -1 -2 4.55 /100 1. Commercial availability ³ 2 1 0 -1 -2 4.55 /100 3. Strategic reserve 4. Capacity of production 5 5 5 5 4. Capacity of production 5 5 5 5 5 5. Market potential 6 Affordable 5 5 5 5 7. Quality/stability 8. Safety of vaccines 5 5 5 100 1. Availability ³ 2 1 0 -1 -2 4.55 /100 1. Availability ⁴ 2 1 0 -1 -2 4.55 /100 1. Availability ⁴ 2 1 0 -1 -2 4.55 /100 1. Availability ⁴	3. Strategic reserve							
 5. Market potential 6. Affordable 7. Quality/stability durability 8. Sensitivity 9. Specificity 10. Reproducibility 11. Simplicity/ease of use 12. Speed Vaccination tools 2 I 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use 9. Efficacy 10. Immunity 11. Convenience of use 9. Efficacy 10. Immunity 11. Convenience of use 12. Speetificity 13. Strategic reserve 4. Capacity of production 14. Vailability³ 15. Market potential 16. Cost 17. Quality 18. Safety only convention 19. Safety environment 11. Resistance 10. Safety environment 11. Resistance 	4. Capacity of production							
6. Affordable 7. Quality/stability durability 8. Sensitivity 9. Specificity 10. Reproducibility 11. Simplicity/ease of use 12. Speed 2 1 0 -1 -2 4.55 /100 10. Commercial availability ^a 2 1 0 -1 -2 4.55 /100 1. Commercial availability ^a 2 1 0 -1 -2 4.55 /100 3. Strategic reserve 4. Capacity of production 5 5 5 5 5 6. Affordable -2 4 5 7 100 -1 -2 4.55 7 7. Quality/stability 3. Strategic reserve 4. Capacity of production 5 5 5 5 100 10. Immunity 11. Convenience of use 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 3. Strateg	5. Market potential							
 7. Quality/stability durability 8. Sensitivity 9. Specificity 10. Reproducibility 11. Simplicity/ease of use 12. Speed Vaccination tools 2 1 0 -1 -2 4.55 /100 1. Commercial availability^a 2. Monitoring for infection in a vaccinated population 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability^a 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 8. Safety of production 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety environment 11. Resistance Total Score: 	6. Affordable							
 8. Sensitivity 9. Specificity 10. Reproducibility 11. Simplicity/ease of use 12. Speed Vaccination tools 2 1 0 -1 -2 4.55 /100 1. Commercial availability^a 2. Monitoring for infection in a vaccinated population 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability^a 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety environment 11. Resistance Total Score: 	7. Quality/stability durability							
9. Specificity 10. Reproducibility 11. Simplicity/ease of use 12. Speed Vaccination tools 2 1 0 -1 -2 4.55 /100 1. Commercial availability ^a 2. Monitoring for infection in a vaccinated population - - 4.55 /100 3. Strategic reserve - <td>8. Sensitivity</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	8. Sensitivity							
10. Reproducibility11. Simplicity/ease of use12. SpeedVaccination tools210-1-24.55/1001. Commercial availabilitya2. Monitoring for infection in a vaccinated population555553. Strategic reserve4. Capacity of production5. Market potential6. Affordable5551007. Quality/stability8. Safety of vaccines9. Efficacy10. Immunity11. Convenience of usePharmaceutical tools210-1-24.55/1001. Availabilitya2. Prevention and control3. Strategic reserve4. Capacity of production5. Market potential6. Affordable7. Quality10. Immunity11. Convenience of usePharmaceutical tools210. Availabilitya2. Prevention and control3. Strategic reserve4. Capacity of production5. Market potential6. Cost7. Quality8. Safety animal9. Safety consumer/user concerns10. Safety environment11. ResistanceTotal Score:	9. Specificity							
11. Simplicity/ease of use12. SpeedVaccination tools210-1-24.55/1001. Commercial availability ³ 2. Monitoring for infection in a vaccinated population4.55/1013. Strategic reserve4. Capacity of production5. Market potential6. Affordable7. Quality/stability8. Safety of vaccines9. Efficacy10. Immunity11. Convenience of usePharmaceutical tools210-1-24.55/1001. Availability ⁸ 2. Prevention and control3. Strategic reserve4. Capacity of production5. Market potential6. Cost7. Quality8. Safety animal9. Safety animal9. Safety consumer/user concerns10. Safety environment11. ResistanceTotal Score:	10. Reproducibility							
12. SpeedVaccination tools210-1-24.55/1001. Commercial availabilitya2. Monitoring for infection in a vaccinated population <t< td=""><td>11. Simplicity/ease of use</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	11. Simplicity/ease of use							
Vaccination tools210-1-24.55/1001. Commercial availabilitya2. Monitoring for infection in a vaccinated population3. Strategic reserve4. Capacity of production5. Market potential6. Affordable7. Quality/stability8. Safety of vaccines9. Efficacy10. Immunity11. Convenience of usePharmaceutical tools210. Availabilitya2. Prevention and control3. Strategic reserve4. Capacity of production5. Market potential6. Affordable7. Quality10. Immunity11. Convenience of usePharmaceutical tools210-1-24.551001. Availabilitya2. Prevention and control3. Strategic reserve4. Capacity of production5. Market potential6. Cost7. Quality8. Safety animal9. Safety consumer/user10. Safety environment11. ResistanceTotal Score:	12. Speed							
 1. Commercial availability^a 2. Monitoring for infection in a vaccinated population 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance 	Vaccination tools	2	1	0	-1	-2	4.55	/100
 2. Monitoring for infection in a vaccinated population 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance 	1. Commercial availability ^a							
 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score: 	2. Monitoring for infection in a vaccinated population							
 4. Capacity of production 5. Market potential 6. Affordable 7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance 	3. Strategic reserve							
5. Market potential 6. Affordable 7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score:	4. Capacity of production							
6. Affordable 7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score:	5. Market potential							
7. Quality/stability 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score:	6. Affordable							
 8. Safety of vaccines 9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score: 	7. Quality/stability							
9. Efficacy 10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2. Prevention and control 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score:	8. Safety of vaccines							
10. Immunity 11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 3. Strategic reserve 4 Capacity of production 5 5 5 5 5 5 5. Market potential 6 Cost 7 Quality 8 5	9. Efficacy							
11. Convenience of use Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2 1 0 -1 -2 4.55 /100 3. Strategic reserve 4 Capacity of production 5 5 5 5 4. Capacity of production 5 Market potential 6 6 5 6 6. Cost 7 Quality 8 Safety animal 5 5 5 5 9. Safety consumer/user concerns 10 Safety environment 5	10. Immunity							
Pharmaceutical tools 2 1 0 -1 -2 4.55 /100 1. Availability ^a 2. Prevention and control 3. 5. 7.	11. Convenience of use							
 Availability^a Prevention and control Strategic reserve Capacity of production Market potential Cost Quality Safety animal Safety consumer/user concerns Safety environment Resistance Total Score: 	Pharmaceutical tools	2	1	0	-1	-2	4.55	/100
 Prevention and control Strategic reserve Capacity of production Market potential Cost Quality Safety animal Safety consumer/user concerns Safety environment Resistance Total Score: 	1. Availability ^a							
 3. Strategic reserve 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score: 	2. Prevention and control							
 4. Capacity of production 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score: 	3. Strategic reserve							
 5. Market potential 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score: 	4. Capacity of production							
 6. Cost 7. Quality 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score: 	5. Market potential							
 Quality Safety animal Safety consumer/user concerns Safety environment Resistance Total Score: 	6. Cost							
 8. Safety animal 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score: 	7. Quality							
 9. Safety consumer/user concerns 10. Safety environment 11. Resistance Total Score: 	8. Safety animal							
10. Safety environment 11. Resistance Total Score:	9. Safety consumer/user concerns							
11. Resistance Total Score:	10. Safety environment							
Total Score:	11. Resistance							
	Total Score:					_		

^aA maximum score of 20 was given to the whole criterion when there isn't any product available (not even under development)

Expert opinion elicitation

An expert group leader was appointed for each disease and was asked to engage other experts. Where possible each group was asked to include experts with laboratory and diagnostic expertise, an epidemiologist, an industry representative and an individual with economic/trade expertise. The leader was expected to organise a physical or e-meeting in order to provide the information as described below. The names of the experts are published on the DISCONTOOLS website.

The average number of experts per group was 7. For 43 of the 52 included diseases (83%) the expert groups involved at least 4 members considered to cover the requested expertise (diagnostic, epidemiology, industry, economics). However for 9 diseases (17%), \leq 3 experts were included (i.e. contagious bovine pleuropneumonia, swine influenza virus, peste des petits ruminants, rift valley fever, liver fluke, bovine herpes virus type 1, leptospirosis, salmonella, Crimean congo haemorrhagic fever).

Utility

DISCONTOOLS website

The DISCONTOOLS website contains two main sections: (i) work group pages and (ii) the disease database. The work group pages contain relevant minutes, documents and presentations related to meetings of the project management board.

The disease database contains the full D&P, along with a 2-page summary to make it easy to interpret the outcome. All the available information can be filtered for specific diseases or specific sections of the analysis and the customized reports can be downloaded in.pdf or.xls format. There is also a tool to enable web site users to provide comments on the D&P to the DISCONTOOLS secretariat. The prioritisation model and gap analysis model can be consulted for one or more diseases simultaneously and the specific scores for individual levels of criteria can be consulted or downloaded through custom reports.

Ranking of diseases by prioritisation model, disease category and gap analysis model

In Table 4, diseases are ranked based on the total score of the prioritisation model. The Table is very useful in terms of providing a 'Big Picture' view and shows that the top ranked diseases comprise mostly zoonotic diseases and epizootic (often exotic) diseases. This, in turn, helps to guide funders who are working in an international environment and with a broad remit in terms of priorities. In Table 5, the diseases were ranked within disease category. This provides an opportunity to identify priorities within different research domains. As such, funders with an interest in public health will look to the zoonoses ranking. In contrast, funders focusing on international trade will have a great interest in the epizootic diseases ranking and funders who are focusing on the efficiency of production, especially within individual countries, will have a great interest in the ranking of food producing animal complexes. The results of the gap analysis model can be used to obtain more details of the gaps in control tools. As an example, in Table 6 we provide the scores of the gap analysis model for diagnostics, vaccines and pharmaceuticals for the top 10 ranked diseases within each disease category. In general, this table highlights the major gap in pharmaceuticals for the epizootic diseases which is not surprising as the availability of antivirals for the majority of diseases is very limited or non-existent at present. In contrast, for the food producing animal complexes, the picture is more diverse with, dependent on the disease, remaining gaps in diagnostics and vaccines and less so in pharmaceutical development. For the zoonotic diseases, good diagnostics are generally available and the analysis highlights the need for research into vaccine development. It should be noted that, whilst the gap is identified, in many cases, it is unlikely that a pharmaceutical solution would be pursued, for example Bluetongue.

Discussion

The aim of the DISCONTOOLS project was to build a prioritisation model and gap analysis on control tools as a means of prioritising research on infectious animal diseases with the support of stakeholders via a very open consultation process in the animal health research community.

The major achievement of this project consists of the wide and standardized consultation of the animal health research community, involving a total of 342 animal health scientists from all over the world. The establishment of expert groups was an important step in itself because it brought together scientists from different backgrounds and expertise often leading to lively debate, the challenge of assumptions and the identification of research gaps within their field. Where expert groups could not reach consensus, this was recorded in the D&P under the "Gap" section because it represents a gap in knowledge that needs to be filled by research.

An example is the benefit of bees to pollination. At the outset of the discussion, it was suggested by some of the participants that crop yields could decline by 65% without bees. However, when it was pointed out that wild insects have a more important role in pollination than honey bees, major crop species such as cereals are self-pollinating and many others are wind pollinated [27], it was agreed that the impact would be considerably less and it was noted that work needs to be done in

Table 4 Ranking of 52 infectious diseases of animals by the overall score of the prioritisation model

Disease	Overall score
Nipah virus	464
Peste des petits ruminants	385
African swine fever	373
Rift valley fever	365
Bovine tuberculosis	359
Foot and mouth disease	310
Non tse-tse transmitted animal trypanosomiasis	296
African horse sickness	294
Cryptosporidiosis	291
Salmonellosis	282
Contagious bovine pleuropneumonia	269
Leishmaniosis	262
Brucellosis	254
Leptospirosis	250
Classical swine fever	247
Lumpy skin disease	244
Bluetongue	241
Orthopox	237
Hepatitis E virus	237
Poultry coccidiosis	226
Paratuberculosis	223
Anthrax	220
Campylobacter	219
Sheep and goat pox virus	218
Q-fever	214
Rabies	212
Avian Influenza	209
Verocytotoxigenic Escherichia coli	209
Liver fluke	202
Chlamydophila abortus	197
Nematodes	193
Porcine circo virus type 2	183
Bovine viral diarrhoea virus	183
Bovine spongiform encephalopathy	180
Small ruminant mastitis	179
Varroa mite	177
Staphylococcus aureus mastitis	175
Theileria	174
Mycoplasma bovis	173
Echinococcosis	167
Swine influenza virus	162
Congo crimean haemorrhagic fever	162
Swine Actinobacillus pleuropneumonia	159

Table 4 Ranking of 52 infectious diseases of animals by the overall score of the prioritisation model (*Continued*)

Bovine respiratory syncytial virus	153
Parapox	152
Swine mycoplasma	143
Cysticercosis	130
Swine vesicular disease	118
West Nile Virus	118
Bovine herpes virus type 1	107
Porcine reproductive and respiratory syndrome virus	107
Environmental/Streptococcal mastitis	83

this area to determine the real impact. Having had this discussion, it was recognised that efforts should be made to control *Varroa* mite as the bee sector – with its various products – is valuable (roughly estimated in the consortium at €640 million per annum) and needs to be protected.

As was done in Table 3, it is possible to rank diseases by total scores of the prioritisation model. The total score is valuable in highlighting the overall importance of some diseases. Nipah virus obtained the highest score. This was an interesting outcome and its high ranking is confirmed in other recent studies to prioritize diseases of food-producing animals and zoonoses [25, 28]. In the case of FMD, it scores highly due to knowledge gaps along with its impact on animal health and welfare, society and trade even though we have good diagnostics and vaccines. Given the impact of the disease, we need heat stable multi-valent vaccines and need to focus research in this area.

It might be surprising that the overall total for FMD (310) in the prioritisation model is lower than that for ASF (373) but an examination of the score in each of the six separate categories (Table 2) which make up the prioritisation model it is apparent where the variation exists. In the case of ASF the score is higher for the impact on international trade, animal health and welfare and significantly higher for control tools where there is no vaccine and diagnostic tests need to be improved.

Despite the maximally standardized consultation rounds and the use of a validation system in the form of Work Packages 2 and 3 and the PMB, the final ranking of diseases should be interpreted with caution. The total scores also hide specific research needs within a disease. In the case of nematodes for example, the total score hides the pressing need to assign resources to the development of vaccines in this area [29]. To avoid the user missing key data, the "Interpretation of the Scores Guide" was developed as well as the two page summary for each disease.

1. Epizootic diseases	Score	2. Food producing animal complexes	Score	3. Zoonoses	Score
Peste des petits ruminants	385	Poultry coccidiosis	226	Nipah virus	464
African swine fever	373	Paratuberculosis	223	Bovine tuberculosis	359
Rift valley fever	365	Liver fluke	202	Non tse-tse transmitted animal trypanosomiasis	296
Foot and mouth disease	310	Nematodes	193	Cryptosporidiosis	291
African horse sickness	294	Porcine circo virus type 2	183	Salmonellosis	282
Contagious bovine pleuropneumonia	269	Bovine viral diarrhoea virus	183	Leishmaniosis	262
Classical swine fever	247	Small ruminant mastitis	179	Brucellosis	254
Lumpy skin disease	244	Varroa mite	177	Leptospirosis	250
Bluetongue	241	Staphylococcus aureus mastitis	175	Hepatitis E virus	237
Orthopox	237	Theileria	174	Anthrax	220
Sheep and goat pox virus	218	Mycoplasma bovis	173	Campylobacter	219
Avian Influenza	209	Swine influenza virus	162	Q-fever	214
Parapox	152	Swine Actinobacillus pleuropneumonia	159	Rabies	212
Swine vesicular disease	118	Bovine respiratory syncytial virus	153	Verocytotoxigenic Escherichia coli	209
West Nile Virus	118	Swine mycoplasma	143	Chlamydophila abortus	197
		Bovine herpes virus type 1	107	Bovine spongiform encephalopathy	180
		Porcine reproductive and respiratory syndrome virus	107	Echinococcosis	167
		Environmental/Streptococcal mastitis	83	Congo crimean haemorrhagic fever	162
				Cysticercosis	130

Table 5 Ranking of 52 infectious diseases of animals by disease category based on the prioritisation model

The latter is of particular assistance to the non-specialist user who wants an overview of the critical research needs. Depending on the aim of the research, it may be more informative to compare specific criteria only between diseases (e.g. disease knowledge, impact on wider society, etc.). Two critical factors that can affect the results are: (i) the choice of the weighting coefficients and (ii) the different composition of each expert group. The different criteria of the prioritisation model such as disease knowledge, impact on animal health and welfare, etc. received an equal weight. However, depending on the user, different weight attributions may be desirable. Recently, novel methods have been developed to identify criteria important to different stakeholders by using the nominal group technique and attribute relative weights to the criteria using a wide consultation of different stakeholders and conjoint analysis [26]. This can result in different rankings according to the criteria and weights defined by different stakeholders (e.g. the public vs. health professionals) and provide additional insights to the decision maker on the spending of research funds [19]. In contrast to other prioritisation studies where all diseases were scored by the same expert panel, e.g. [13, 28], in the DISCONTOOLS project, each disease was scored by a different expert panel. This may have introduced bias due to inter-personal differences in scoring, but was considered necessary in order to adequately capture the current status of knowledge and gaps for control tools for each disease.

The epidemiological situation of infectious animal diseases can change rapidly (e.g. the current epidemic of the new porcine epidemic diarrhoea virus [30]), and biotechnological developments constantly change the landscape of diagnostics, vaccines and pharmaceuticals. As a consequence, the prioritisation exercise should be repeated regularly [28]. To this end, the database has been placed on a public website with the possibility that the public and research community can provide comments. This was deliberately done to provide an environment where the information in the D&P and the scores could be challenged. The idea is to gather comments over time and then ask the expert group to consider comments made and adjust the information and scoring on the site as appropriate. It is foreseen that the diseases will be systematically reviewed by the expert groups over a 5-year cycle, taking on board the latest technical advances. In fact, this process has already commenced and updated information on the site is available for African swine fever, Foot and mouth disease, Nematodes and Verocytotoxigenic E. coli.

Conclusion

A database was established with the intention of identifying and prioritising research needs in the control of infectious

Disease	Diagnostics	Vaccines	Pharmaceuticals
1. Epizootic diseases			
Peste des petits ruminants	-5	-10	20
African swine fever	-50	40	40
Rift valley fever	29	18	40
Foot and mouth disease	-32	-20	40
African horse sickness	-18	20	10
Contagious bovine pleuro pneumonia	9	30	25
Classical swine fever	-23	-50	40
Lumpy skin disease	27	-5	40
Bluetongue	-27	-15	40
Orthopox	18	40	15
2. Food producing animal com	plexes		
Coccidiosis	9	5	-35
Paratuberculosis	0	0	40
Liver fluke	-9	40	-25
Nematodes	-5	40	-65
Bovine viral diarrhoea virus	-27	-10	40
Porcine circo virus type 2	20	-40	40
Small ruminant mastitis	-23	-5	-50
Varroa mite	40	40	-10
<i>Staphylococcus aureus</i> mastitis	14	0	-30
Theileria	27	40	-30
3. Zoonotic diseases			
Nipah virus	0	0	0
Bovine tuberculosis	-18	10	40
Non tse-tse transmitted trypanosomiasis	32	40	15
Cryptosporidiosis	0	40	-45
Salmonellosis	-23	-30	-35
Leishmaniosis	-14	35	-20
Brucellosis	-5	20	40
Leptospirosis	-5	5	-60
Hepatitis E virus	-32	40	40
Anthrax	36	5	-45

Table 6 Scores from the gap analysis model for the top-10 ranked diseases within each disease category^a

Positive scores (indicating a gap) were highlighted in bold

^aDecimals were rounded to the first integer. This may cause apparent deviations between the sum of the individual and the total score

animal diseases in the EU. If the focus of research is now placed on the priorities identified, it will hasten the development of diagnostics, vaccines and pharmaceuticals and reduce the 20% loss in production potential, valued at \in 28 billion per year in the EU. Funders of research including the European Commission, member states, foundations, trusts along with private industry should use the database

to prioritise and focus future research. This will deliver benefits in terms of animal health and welfare but also public health, societal benefits and a safe and secure food supply. The employed method and results should not be considered fixed, but by refining the scoring methodology, challenging and updating the available information on a regular basis and incorporating new diseases, the DISCONTOOLS database has the potential to become a reference point used by stakeholders when prioritising research.

Endnotes

¹www.etpgah.eu

Abbreviations

D&P: Disease and Product analysis document; ETPGAH: European Technology Platform for Global Animal Health; EU: European Union; OIE: World Organisation for Animal Health; PMB: Project Management Board

Acknowledgements

We wish to thank all Expert Group leaders and members of Expert Groups and stakeholders for their invaluable contribution to the success of the DISCONTOOLS Project.

Funding

This project was funded by the 7th framework programme of the EU (grant agreement number 211316) and currently receives funding from different research funding bodies from EU member states.

Availability of data and materials

The database generated during this project is publicly available on www.discontools.eu.

Authors' contributions

DOB conceived the study, coordinated the project and supervised the manuscript. JS assisted in project management, wrote the manuscript and the disease summaries. JC wrote the manuscript and manages the database from 2014. MD managed the project and maintained the database from 2008 to 2013. All authors read and approved the final manuscript.

Authors' information

DOB was the coordinator of the project under the 7th framework programme on behalf of IFAH-Europe but is currently no longer employed by this organisation. JC is the current project manager commissioned by IFAH-Europe.

Competing interests

Being a stakeholder driven project, all those involved in the chain from research to commercialisation of products including universities, regulators, farming and veterinary representative organisations along with the pharmaceutical industry contributed to the outcome of this study. The authors declare that they have no financial or personal relationships with other people or organisations that could have inappropriately influenced the present study and manuscript.

Consent for publication

Name of disease experts are published below the disease information where written consent has been given. Experts retain the right to access, change or remove their personal data.

Ethics approval and consent to participate

Not applicable.

Author details

¹International Federation for Animal Health Europe, Avenue de Tervueren 168, box 81150 Brussels, Belgium. ²Institute of Infection and Global Health, University of Liverpool, Liverpool, UK. ³Avia-GIS, Risschotlei 33, 2980 Zoersel, Belgium.

Received: 11 December 2015 Accepted: 17 December 2016 Published online: 03 January 2017

References

- Vallat B. One World, One Health. In: Editorials from the Director-General. Publisher: World Organisation for Animal Health (oie). 2009. http://www.oie. int/en/for-the-media/editorials/detail/article/one-world-one-health/. Accessed 20 Aug 2014.
- Benmansour A. Animal Health and Welfare ERA-net (anihwa). 2012. https:// www.anihwa.eu/About-Anihwa/Project-description. Accessed 20 Aug 2014.
- 3. Anonymous. Common financial framework for the food chain. 2014. http:// ec.europa.eu/food/animal/diseases/index_en.htm. Accessed 20 Aug 2014.
- 4. IFAH. Annual Report 2013 International Federation for Animal Health-Europe. 2014. p. 12.
- EUROSTAT. Key figures on Europe, 2013 digest of the online Eurostat yearbook. Luxembourg: Piirto Jukka; 2013. p. 184.
- European Technology Platform for Global Animal Health. Action plan. 2007. http://www.etpgah.eu/action-plan.html. Accessed 20 Aug 2014, 52 pp.
- Rushdy A, O'Mahony M. PHLS overview of communicable diseases 1997: results of a priority setting exercise. Commun Dis Rep CDR Wkly. 1998;8:S1–S12.
- Weinberg J, Grimaud O, Newton L. Establishing priorities for European collaboration in communicable disease surveillance. Eur J Public Health. 1999;9:236–40.
- Doherty JA. Establishing priorities for national communicable disease surveillance. Can J Infect Dis. 2000;11:21–4.
- Horby P, Rushdy A, Graham C, O'Mahony M. PHLS overview of communicable diseases 1999. Comm Dis Publ Health. 2001;4:8–17.
- WHO. Setting priorities in communicable disease surveillance. Global Alert and Response publications. 2006; 32 pp.
- Krause G, Working Group on Prioritisation at the Robert Koch Institute. Prioritisation of infectious diseases in public health–call for comments. Euro Surveill. 2008;13(40):18996.
- Cardoen S, Van Huffel X, Berkvens D, Quoilin S, Ducoffre G, Saegerman C, Speybroeck N, Imberechts H, Herman L, Ducatelle R, Dierick K. Evidencebased semiquantitative methodology for prioritization of foodborne zoonoses. Foodborne Pathog Dis. 2009;6:1083–96.
- Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gartner B, Gross U, Haas W, Hamouda O, Hubner J, Janisch T, Kist M, Kramer MH, Ledig T, Mielke M, Pulz M, Stark K, Suttorp N, Ulbrich U, Wichmann O, Krause G. Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011. Plos One. 2011;6:e25691.
- Cox R, Sanchez J, Revie CW. Multi-criteria decision analysis tools for prioritising emerging or re-emerging infectious diseases associated with climate change in Canada. Plos One. 2013;8:e68338.
- Havelaar AH, van Rosse F, Bucura C, Toetenel MA, Haagsma JA, Kurowicka D, Heesterbeek JH, Speybroeck N, Langelaar MF, van der Giessen JW, Cooke RM, Braks MA. Prioritizing emerging zoonoses in the Netherlands. Plos One. 2010;5:e13965.
- Ng V, Sargeant J. An empirical and quantitative approach to the prioritization of zoonotic diseases of public health importance in Canada. Ecohealth. 2011;7:S114.
- Sargeant J, Ng V. The current state of knowledge of zoonoses and the implications for research outcomes in disease prioritization in Canada. Ecohealth. 2011;7:S34.
- Ng V, Sargeant JM. A quantitative approach to the prioritization of zoonotic diseases in north America: a health professionals' perspective. Plos One. 2013;8:e72172.
- 20. FAO/WHO. Multicriteria-based ranking of risk management of food-borne parasites. Microbiological Risk Assessment Series. 2014;23:302.
- McKenzie J, Simpson H, Langstaff I. Development of methodology to prioritise wildlife pathogens for surveillance. Prev Vet Med. 2007;81:194–210.
- Heffernan C. Panzootics and the poor: devising a global livestock disease prioritisation framework for poverty alleviation. Rev Sci Tech – OIE. 2009;28:897–907.
- More SJ, McKenzie K, O'Flaherty J, Doherty ML, Cromie AR, Magan MJ. Setting priorities for non-regulatory animal health in Ireland: Results from an expert Policy Delphi study and a farmer priority identification survey. Prev Vet Med. 2010;95:198–207.
- Vilas VJD, Voller F, Montibeller G, Franco LA, Sribhashyam S, Watson E, Hartley M, Gibbens JC. An integrated process and management tools for ranking multiple emerging threats to animal health. Prev Vet Med. 2013;108:94–102.

- Brookes VJ, Hernandez-Jover M, Cowled B, Holyoake PK, Ward MP. Building a picture: prioritisation of exotic diseases for the pig industry in Australia using multi-criteria decision analysis. Prev Vet Med. 2014;113:103–17.
- Ng V, Sargeant JM. A stakeholder-informed approach to the identification of criteria for the prioritization of zoonoses in Canada. Plos One. 2012;7:e29752.
- 27. Garibaldi LA, Steffan-Dewenter I, Winfree R, Aizen MA, Bommarco R, Cunningham SA, Kremen C, Carvalheiro LG, Harder LD, Afik O, Bartomeus I, Benjamin F, Boreux V, Cariveau D, Chacoff NP, Dudenhoffer JH, Freitas BM, Ghazoul J, Greenleaf S, Hipolito J, Holzschuh A, Howlett B, Isaacs R, Javorek SK, Kennedy CM, Krewenka KM, Krishnan S, Mandelik Y, Mayfield MM, Motzke I, Munyuli T, Nault BA, Otieno M, Petersen J, Pisanty G, Potts SG, Rader R, Ricketts TH, Rundlof M, Seymour CL, Schuepp C, Szentgyorgyi H, Taki H, Tscharntke T, Vergara CH, Viana BF, Wanger TC, Westphal C, Williams N, Klein AM. Wild pollinators enhance fruit set of crops regardless of honey bee abundance. Science. 2013;339:1608–11.
- Humblet MF, Vandeputte S, Albert A, Gosset C, Kirschvink N, Haubruge E, Fecher-Bourgeois F, Pastoret P-P, Saegerman C. Multidisciplinary and evidence-based method for prioritizing diseases of food-producing animals and zoonoses. Emerg Infect Dis. 2012;18. doi: 10.3201/eid1804.111151
- Vercruysse J, Schetters TPM, Knox DP, Willadsen P, Claerebout E. Control of parasitic diseases using vaccines: an answer to drug resistance? Rev Sci Tech – OIE. 2007;26:105–15.
- Chen Q, Li G, Stasko J, Thomas JT, Stensland WR, Pillatzki AE, Gauger PC, Schwartz KJ, Madson D, Yoon KJ, Stevenson GW, Burrough ER, Harmon KM, Main RG, Zhang J. Isolation and characterization of porcine epidemic diarrhea viruses associated with the 2013 disease outbreak among swine in the United States. J Clin Microbiol. 2014;52:234–43.

Page 10 of 10

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

